

Lyudmila Bazhenova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1803719/publications.pdf>

Version: 2024-02-01

26
papers

3,944
citations

394390

19
h-index

552766

26
g-index

26
all docs

26
docs citations

26
times ranked

6014
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2598-2608.	4.1	1,779
2	Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 813-824.	27.0	505
3	Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 241-251.	27.0	393
4	Adagrasib in Non-Small-Cell Lung Cancer Harboring a <i>KRAS</i> ^{G12C} Mutation. <i>New England Journal of Medicine</i> , 2022, 387, 120-131.	27.0	269
5	Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial. <i>Cancer Discovery</i> , 2021, 11, 1688-1699.	9.4	154
6	First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced <i>KRAS</i> ^{G12C} Solid Tumors (KRYSTAL-1). <i>Journal of Clinical Oncology</i> , 2022, 40, 2530-2538.	1.6	130
7	Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. <i>Cancer</i> , 2019, 125, 892-901.	4.1	117
8	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With <i>EGFR</i> -Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1907-1918.	1.1	85
9	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <i>NTRK</i> Fusion-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1302-1312.	7.0	74
10	Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4160-4167.	7.0	64
11	Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1139-1145.	2.5	63
12	Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 294.	4.4	45
13	Stereotactic Body Radiation Therapy in Octogenarians With Stage I Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 131-135.	2.6	38
14	New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661879413.	2.6	35
15	Sunvozertinib, a Selective <i>EGFR</i> Inhibitor for Previously Treated Non-Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations. <i>Cancer Discovery</i> , 2022, 12, 1676-1689.	9.4	30
16	Phase 2 Study of Erlotinib in Combination With Afatinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. <i>Clinical Lung Cancer</i> , 2017, 18, 34-42.e2.	2.6	29
17	Entropy, complexity and Markov diagrams for random walk cancer models. <i>Scientific Reports</i> , 2014, 4, 7558.	3.3	28
18	TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting. <i>Targeted Oncology</i> , 2021, 16, 389-399.	3.6	24

#	ARTICLE	IF	CITATIONS
19	Adrenal Metastases in Lung Cancer: Clinical Implications of a Mathematical Model. Journal of Thoracic Oncology, 2014, 9, 442-446.	1.1	23
20	Advances in Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Clinics in Chest Medicine, 2020, 41, 223-235.	2.1	18
21	A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 4566-4573.	7.0	13
22	Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs). Lung Cancer: Targets and Therapy, 2021, Volume 12, 21-34.	2.7	10
23	Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer, 2021, 159, 56-65.	2.0	7
24	ROS1-rearranged Non-Small Cell Lung Cancer. Thoracic Surgery Clinics, 2020, 30, 147-156.	1.0	5
25	Abstract P02-01: Repotrectinib in patients with <i>NTRK</i> fusion-positive advanced solid tumors: update from the registrational phase 2 TRIDENT-1 trial. Molecular Cancer Therapeutics, 2021, 20, P02-01-P02-01.	4.1	5
26	An overview of alectinib hydrochloride as a treatment option for ALK positive non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2021, 22, 1815-1824.	1.8	1